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The purpose of our study was to evaluate the performance and
clinical usefulness of an automated injector system (AIS) that
administers an automated injection for ictal SPECT after cal-
culating the volume of tracer to be injected over time.Methods:
To test the AIS, repeated injections were performed at different
times after tracer preparation. The clinical study consisted of 56
patients with drug-resistant, complex partial seizures. Tracer for
ictal SPECT was injected using automated injection in 27
patients and manual injection (MI) in the remaining 29. Injection
time (TI) was measured in seconds from seizure onset to the
end of volume injection. The SISCOM (Subtraction Ictal Spect
Co-registered to MRI) procedure was used to locate the epilep-
togenic seizure focus with SPECT. The definition of seizure
focus was made by consensus of the epilepsy unit using con-
ventional diagnostic methods. Results: During the experimental
phase, there were no system failures, and the error in injected
doses when using automated injection was lower than with MI.
During the clinical phase, TI using manual injection was 41 s
with a range of 14–103 s, compared with an AIS average of 33 s
with a range of 19–63 s (P , 0.05). Ictal SPECT and SISCOM
successfully localized the seizure focus in 21 of the 27 patients
(78%) by AIS and in 19 of the 29 patients (65%) by MI (P 5
0.14). Furthermore, nursing staff found the AIS method more
convenient than the MI method. Conclusion: An AIS can im-
prove the quality of work of the nursing staff in the neurology
ward and allow a finer adjustment of the injection dose. Early
results using an AIS would indicate a reduction in injection time
and improved SPECT accuracy.
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Medically intractable complex partial seizures can be
cured or improved using surgery, but accurate preoperative
localization of the seizure focus is essential for complete
seizure control. Videoelectroencephalogram (V-EEG) mon-
itoring is the method of choice for localizing the seizure
focus. However, a scalp electroencephalogram is often in-
adequate, especially for deep lesions or in rapidly spreading
seizures, which it either fails to register or identifies as
propagation rather than seizure onset (1). Structural and
functional imaging procedures have been used to supple-
ment electroencephalogram findings, avoiding invasive re-
cordings with intracranial electrodes. MRI and ictal and
interictal SPECT are the most frequently used procedures
for localizing the seizure focus. Of these imaging tech-
niques, ictal SPECT is the only one that can actually record
the seizure onset zone (2).
Obtaining a good ictal SPECT study is not always
easy, however, because a seizure is a dynamic process in
which several brain regions can become involved sequen-
tially (3,4). 99mTc-labeled with hexamethylpropylene-
amine-oxine (99mTc-HMPAO) is injected during the
epileptic seizure. Because of increased local cerebral blood
flow during the seizure, a brain SPECT scan will show an
increase in tracer uptake in the onset zone (5). If there is
a delay in administering the tracer dose after seizure onset,
the epileptic discharge can have already finished or propa-
gated to distant cortical regions by the time of tracer in-
jection (1,6,7). A second limitation of ictal SPECT is the
technically complex procedure required for injection.
To address these limitations, our unit developed an
automatic injection system (AIS) that is activated from
a remote-control module and injects the dose automatically
when the patient goes into epileptic seizure. In this paper,
we describe our experience with this AIS and the quality
control procedures that were performed before its use on
patients. The clinical usefulness of an automatic injection
(AI) to inject ictal SPECT doses to epileptic patients was
evaluated and compared with the manual injection (MI)
method.
MATERIALS AND METHODS
AIS
The AIS consists of a 2-part module that communicates via
radiofrequency and an injection pump containing the radioactive
dose (Fig. 1).
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The remote-control module has 2 buttons to initiate injection
and a security key. The module is installed in the electroenceph-
alogram technicians’ room. When technicians detect a seizure,
they push the buttons to activate the AIS.
The pump-control module has a keyboard and display for the
input data relating to dose calibration and the parameters required
for tracer injection. The microprocessor calculates injected volume
(VI) as a function of calibrated dose activity (Acal) and calibration
volume (Vcal) at the time between calibration and injection. This
module is located next to the patient’s bed and connected to the
pump. The data regarding calibration dose that are keyed into the
pump-control module are the Acal in megabecquerels, Vcal in milli-
liters, and calibration time (tcal). The parameters required for in-
jection are the theoretic activity to be injected (AI), the dead volume
(Vdead) in the pressure extension line, and the dose expiration time.
Using all introduced data, we calculated the VI at time t as:

VI 5
AI ·Vcal
Acal · e 2 lðtcal 2 tÞ
1 Vdead;

Eq. 1
where l is the disintegration constant for 99mTc, and t the time of
injection.
An Asena GH-Alaris infusion pump was chosen because it can
be controlled by an RS232 serial interface and is already in use at
our hospital for controlled infusion of medication. A radioactive
tracer of 99mTc-HMPAO is placed in the pump in a syringe for
bolus infusion. A pressure extension line filled with heparin and
normal saline is connected directly from the syringe to a vein in
the patient’s forearm, prepared for intravenous injection. The in-
jection pump is shielded in a 3-mm-thick lead-lined box.
Experimental Phase
System Control. Before its use in patients, a series of quality
control tests was performed in the nuclear medicine laboratory.
The tests were performed at 30-min intervals over a 4-h period,
with 3 repetitions at each time. All tests were performed using
a syringe filled with a standard activity (Acal) of 2,220 MBq of
99mTc-pertechnetate in a volume (Vcal) of 4 mL.
Clinical Phase
Patients. The study included 56 consecutive prospective
patients with drug-resistant complex partial seizures who were
undergoing presurgical evaluation. Tracer injection for ictal
SPECT was performed using AI in 27 patients (mean age, 33 y;
11 men and 16 women) and using MI in the remaining 29 patients
(mean age, 36 y; 13 men and 16 women. All patients underwent
ictal and interictal SPECT, V-EEG monitoring, and MRI. All
subjects gave written informed consent before entering the study.
The hospital’s ethical committee approved the use of the AIS on
patients.
V-EEG Monitoring and Seizure Focus Localization. V-EEG
monitoring was performed in the epilepsy unit for 1 wk, using
Nicolet BMSI 5000 equipment with 64 channels (8). Ictal scalp
recordings were obtained using scalp electrodes placed in accor-
dance with the international 10/20 system. Times of seizure onset
and end of injection (TI) were obtained by reviewing the V-EEG.
Seizure onset was defined as the time of earliest indication of
auras or the beginning of rhythmic ictal discharge in the electro-
encephalogram. The seizure focus was defined by a consensus of
the epilepsy unit by means of V-EEG monitoring, MRI, and clin-
ical and neuropsychologic data.
Tracer Injection for SPECT. The programmed dose of 99mTc-
HMPAO was 925 MBq for both injection systems. For MI, a 10-
mL syringe filled with stabilized 99mTc-HMPAO (138 MBq/mL)
was stored in a lead container beside the patient’s bed. MI of the
ictal SPECT was performed by an experienced nurse, trained to
inject radioactive material, who was waiting for a seizure in the
electroencephalogram technicians’ room, next to the patient’s
room. The time taken by the electroencephalogram technician to
identify a clinical seizure as confirmed in the electroencephalo-
gram (TSI) is the time between seizure onset and the order to start
injection. After this, the manual time (Tmanual) is the time it takes
the nurse to go to the patient’s room, open the lead-shielded con-
tainer, take out the syringe containing 99mTc-HMPAO, and intra-
venously inject a volume of 8 mL, if seizure occurs in the first 2 h,
or 10 mL, if it occurs between 2 and 4 h after tracer preparation.
This injected volume guarantees a dose of between 820 and 1,042
MBq of 99mTc-HMPAO. The TI for MI (TMI) is the time from
seizure onset to the end of injection, and the formula used was
TMI 5 TSI 1 Tmanual.
For AI, to reduce injection time, we minimized the volume to
be injected, increasing the activity concentration during the tracer
preparation (9,10). A volume of 4 mL of stabilized 99mTc-HMPAO
with a concentration of 539 MBq/mL was introduced in a syringe
that was placed in the pump ready for the injection. When the
technicians detected a clinical seizure, confirmed by electroen-
cephalogram changes, they pushed the 2 buttons on the remote-
control module (TSI). To calculate the TI for AI (TAI), the formula
FIGURE 1. AIS (Asena GH-Alaris) pump containing radioactive
dose, fixed inside lead-shielded box (A). Pump is connected to
patient’s forearm via pressure extension line filled with heparin
and normal saline. Pump is also connected to pump-control mod-
ule, which activates pump to inject precise volume of tracer to allow
for radioactive decay. At electroencephalogram technicians’ work-
station (B), technician supervises V-EEG of patient and is ready to
push remote-control module buttons when seizure is detected.
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used was TAI 5 TSI 1 Tpump, where Tpump is the time required for
the pump to inject VI.
MRI and SPECT. MRI was performed using a 3-T unit (Tim
Trio; Siemens) with a specific epilepsy protocol. Ictal and
interictal studies were acquired with the same protocol, using
a dual-head SPECT system (Infinia; GE Healthcare) with a low-
energy high-resolution parallel-hole collimator. To assess and
accurately locate the epileptogenic seizure focus before surgery,
we used the SISCOM (Subtraction Ictal Spect Co-registered to
MRI) procedure (11–13) with our own customized software
(focusDET). Software description and acquisition parameters for
MRI and SPECT are set out in the supplemental data (supplemen-
tal materials are available online only at http://jnm.snmjournals.
org).
Ictal SPECT and SISCOM images were analyzed by 2
experienced physicians who were unaware of the clinical and
radiologic findings. SPECT localized the seizure focus when an
increase of perfusion in the ictal SPECT images was confirmed by
the SISCOM images. SPECT findings were compared with the
seizure onset zone as determined by conventional diagnostic
methods.
Statistical Analysis. To assess whether TI was higher with TMI
than with TAI (unilateral hypothesis), a Student t test for indepen-
dent samples was used, and P values of 0.05 or less were consid-
ered as significant. The ability of SPECT to localize the seizure
focus with AI and with MI was compared using the x2 test. For
both injection procedures, the error in injected dose was calculated
as a percentage at different times over a 4-h period.
RESULTS
Experimental Phase
System Control. There was no system failure in any of
the tests. When the AIS was used, the VI of 99mTc-HMPAO
necessary to guarantee an injected dose of 925 MBq was
readjusted electronically from 3–4 mL over a 4-h period.
Because the injection rate for this pump is 0.333 mL/s, plus
a dead time of 4 s, the values of Tpump ranged from 13 to 16
s (average, 14.5 s). The error between VI and measured dose
activity in the 24 tests performed was 1.4% 6 0.7%. Figure
2 shows the interval of confidence of this error.
With MI, to compensate for radioactive decay of 99mTc,
the volume is readjusted once during the 4-h period. Figure
2 also shows the theoretic error between programmed the-
oretic dose and injected dose with this readjustment, allow-
ing a comparison of errors made by the 2 injection systems.
Clinical Phase
Patients. The most relevant clinical data, MRI findings,
and clinical seizure focus localization are summarized in
Table 1.
Tracer Injections for Ictal SPECT. TI values for each
patient of the MI and AI groups are shown in Figure 3.
Average TMI was 41 6 21 s (mean 6 SD), with a range
of 14–103 s (Fig. 3A), whereas the average TAIwas 336 12 s,
with a range of 19–63 s. (Fig. 3B). Reduction in TI using AI
was 8 s on average, and this difference was statistically
significant (P , 0.05). With MI, the average TSI was 19
FIGURE 2. Continuous line shows theoretic error in dose admin-
istration (in %) using MI at different times (over 4-h period at 30-min
intervals) after tracer preparation. Dashed line shows error confi-
dence interval using AI.
TABLE 1
Clinical Data
Parameter AI MI
Patients (n 5 56) 27 29
Mean age 6 SD 33 6 13 36 614
Mesial temporal seizures (n 5 17) 7 10
Neocortical seizures (n 5 39) 20 19
MRI
Normal 6 4
Mesial temporal sclerosis 7 11
Focal MDC* 10 7
Malacia 3 4
Atrophy 0 1
Tumor 1 2
Seizure focus
Temporal 11 14
Frontal 8 10
Parietal 1 3
Occipital 1 0
Temporoparietal 5 2
Hemispheric 1 0
*Focal MDC 5 malformation of cortical development (17
patients), that includes focal cortical dysplasia (15 patients) and
focal subependymal heterotopias (2 patients).
TABLE 2
Features of Injection and Seizure of Ictal SPECT
Parameter AI MI P
Mean duration of
seizures 6 SD
68 649 92 6 71 0.14
Aura 5 4
Postictal injections 7 3
TSI (s) 18 6 12 19 6 22 0.85
Tpump and Tmanual (s) 15 6 1 22 6 9 0.0001*
TI (s) 33 6 12 41 6 21 0.035*
*Statistically significant at the P , 0.05 level.
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6 22 s, with a range of 4–91 s; with AIS, the average TSI
was 18 6 12 s, with a range of 4–50 s. This difference was
not statistically significant (P 5 0.85). However, the aver-
age Tpump, 156 1 s, was significantly inferior to the Tmanual,
22 6 9 s (P , 0.05) (Table 2). Auras before the electroen-
cephalogram changes were observed in 9 patients: 5 with
AI (patients 1, 9, 11, 15, and 24) and 4 with MI (patients,
14, 20, 25, and 27) (Fig. 3). In patients with aura, TI is
usually long, because TSI was counted from the start of
the aura. Tracer injection was postictal in only 10 of 56
patients: 7 with AI and 3 with MI. The mean duration of
seizures was shorter in the AI group of patients, but the
difference was not statistically significant (Table 2), and 7
of 9 postictal AIS injections took place in seizures shorter
than 17 s.
Ictal SPECT and SISCOM demonstrated hyperperfusion
that localized the seizure focus in 21 of 27 (78%) patients
by AI and in 19 of 29 (65%) patients by MI, and these
differences were not statistically significant (P 5 0.14)
(Fig. 4). Ictal SPECT correctly lateralized the seizure onset
side but not the correct lobe in 2 patients with AI and in
another 2 patients with MI. Negative and discordant results
between ictal SPECT and the seizure focus were detected in
4 patients with AI. In 3 of these, SISCOM was negative,
and in 1 case (patient 11), SISCOM showed ictal activity in
the left frontal lobe, contralateral to the seizure focus. SIS-
COM with MI was normal in 4 patients and showed ictal
hyperperfusion in the contralateral side in another 4
patients. In the group of 17 patients with mesial temporal
lobe epilepsy, the SPECT with AI correctly localized 6 of 7
(86%) patients and with the MI 7 of 10 (70%) patients. In
the 39 patients with neocortical epilepsy, SPECT with AI
correctly localized 15 of 20 (75%) patients, whereas
SPECT with MI localized 12 of 19 (63%) patients (Fig. 4).
DISCUSSION
The biggest drawback of ictal SPECT is that the
radiotracer is given manually, a slow and complex process
FIGURE 3. TI in seconds for each patient:
29 patients injected using MI (TMI 5 TSI 1
Tmanual) (A) and 27 patients injected using AI
(TAI 5 TSI 1Tpump) (B).
AUTOMATIC ICTAL SPECT INJECTION • Setoain et al. 327
requiring dedicated personal bedside attention for extended
periods. AIS was first introduced in 1998 by Sepkuty et al.
(14), to optimize management of tracer injection and re-
duce injection latencies. However, their automatic system is
based on a standard injection pump that does not provide an
automatic control of dose activity. A manual self-injector
was described 2 y later by Van Paesschen et al. (15). In this
system, the injection is pushed manually in only 8 s and can
be administered by the patient him- or herself. However, the
system is not automated and does not calculate the volume
to be injected. The third automated injection system
for ictal SPECT presented in the medical literature is
a CT-contrast agent injection pump adapted to inject
99mTc-HMPAO in a bolus (16). Remote control and a higher
velocity result in a short TI of 17 s. The disadvantage is that
the volume to be administered must be precalculated and
adjusted manually every hour to accommodate radioactive
decay.
Our AIS is similar to the automated injector described by
Sepkuty et al. (14). Both systems use the same pump, with
a bolus injection rate of 0.333 mL/s. However, our equip-
ment overcomes the main limitations of Sepkuty’s injector
system by incorporating a remote-control system and soft-
ware to automatically calculate the volume injected, allow-
ing for the radioactive decay of 99mTc.
The possible error in injected dose with MI is highly
variable and depends on the moment when injection takes
place (Fig. 2). On the other hand, AIS guarantees the in-
jection of 925 MBq, with a maximum error of 63% over
a 4-h period. So, for most of the time, the error in injected
dose was greater for MI than for AI.
The AIS is well accepted by the nurses and electroen-
cephalogram technologist of our unit, because the remote-
control system reduces the level of stress produced at
seizure onset and the pump reduces the risk of radioactive
contamination, as opposed to measuring a radioactive
dosage manually in a hurry. An automated injection system
could have other applications in the nuclear medicine
department to reduce the risk of personal irradiation and
contamination during injection of therapeutic doses, cardiac
stress studies, and even in PET.
Our average TAI (33 s) was faster than TMI (41 s). Two
main factors affect the equation TI 5 TSI 1 Tpump or Tmanual.
TSI is extrinsic and thus variable because it depends on the
electroencephalogram technician’s experience and the type
of seizure. However, the average TSI for AI (18 s) was similar
to that of MI (19 s), and these differences were not statisti-
cally significant (P5 0.85). On the other side, Tpump (15 s) is
intrinsic to the AIS, because it depends on the pump rate
(0.333 mL/s) and on an invariable dead time of the system of
4 s. Tmanual (22 s) is the average time that it takes the nurse to
go to the patient’s room, take out the syringe from the lead-
shielded container, and intravenously inject the tracer. Al-
though the TSI of both injection systems was similar, AI was
faster than MI because Tpump is faster than Tmanual (P ,
0.05).
Our TSI for AI (18 s) was higher than that of other groups
(14,16), because in our study the aura was included in the
TSI. In fact, as we can see in Figure 3A, the Tmanual of 3
patients with aura (patients 14, 20, and 27) was short, only
13 s on average because an aura gives the technician time to
prepare the manual dose for injection once the seizure has
started.
Ictal SPECT obtained with the AI detected the seizure
focus more frequently than with the MI (78% vs. 65%),
although these differences were not statistically significant.
The manual TI in our sample is short (average, 41 s), thanks
to the experience of our technicians in the injection of
tracer under these conditions. The length of time needed
for MI in epilepsy units with less experience in ictal SPECT
would probably be greater.
Figure 4 shows that ictal SPECT with AI correctly local-
ized the seizure focus, with high sensitivity in both tempo-
ral (86%) and neocortical (75%) epilepsy. However, when
tracer was injected manually, the sensitivity of ictal SPECT
remained high in temporal lobe epilepsy (70%) but de-
creased in neocortical epilepsy (63%). It seems that in neo-
cortical seizures, which are usually shorter, ictal SPECT
sensitivity is higher when AI is used.
CONCLUSION
An automated system simplifies radioactive dose in-
jection during seizures, making this procedure more
accessible. Benefits include the possibility of maintaining
the tracer at the patient’s bedside for a longer time, with
significantly less stress for the nurses and electroencephalo-
gram technologists and a finer adjustment of the ictal in-
jection dose. Early results using an AIS are promising in
reducing injection time and improving SPECT accuracy. A
FIGURE 4. Percentages of successful seizure focus localization
with ictal SPECT, using MI or AIS.
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commercially manufactured injection system would help
extend the use of ictal SPECT to more nuclear medicine
departments.
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